作者: Tachibana, Yuki ; Akiyama, Toshiyuki ; Tanaka, Satoru ; Hirai, Keiichiro ; Nobori, Haruki ; Tomida, Yutaka ; Taoda, Yoshiyuki ; Uehara, Shota ; Nakahara, Kenji ; Unoh, Yuto ; Kato, Teruhisa ; Kawashima, Sho ; Sako, Yusuke ; Sugiyama, Shuichi ; Yamamoto, Shiho

COVID-19, an infectious disease caused by SARS-CoV-2, first identified in Wuhan, China, in 2019 and rapidly spread around the world. In response to this worldwide crisis, the research and development of antiviral drugs advanced together with vaccines, and several medications are currently being used for treatment. This study aimed to explore the structure-activity relationships (SAR) of non-covalent inhibitors of the SARS-CoV-2 3CL protease (3CL^pro) and to develop more potent inhibitors starting from ensitrelvir, a potent non-peptide small-molecule 3CL^pro inhibitor discovered by Shionogi & Co., Ltd. Although a previously reported dihydrofuran-ring-fused tricyclic compound 1 exhibited high antiviral activity, there were issues with its metabolic stability and solubility. Therefore, we focused on compound 2, which has a pyridopyrimidinedione scaffold, and tried to optimize its structure. Here we report compounds that have improved antiviral activity while maintaining enzyme inhibitory activity and enhanced solubility. In particular, compound 18f demonstrated a balance of potent activity, high solubility, and excellent metabolic stability. Its favorable pharmacokinetics were also confirmed in rat PK tests, suggesting that this compound offers promise as a new therapeutic agent.

2026-05-02·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Impact of Early Oral Antiviral Use for Outpatients With COVID-19 on Healthcare Utilization and Recovery (ANCHOR-02).

Article

作者: Kinoshita, Masahiro ; Murayama, Hiroyuki ; Monma, Eiji ; Yoden, Takahiro ; Morikawa, Nobuyuki ; Nakagawa, Hidemitsu ; Takahashi, Yusaku ; Higa, Hikari ; Shintani, Ayumi ; Nishiguchi, Sho ; Kudo, Naoko ; Maeda, Yohei ; Kakii, Bumpachi ; Asami, Sadaharu ; Hibino, Makoto ; Higashiue, Shinichi

OBJECTIVES:

To evaluate the associations of early-phase oral antivirals with recovery in outpatients with COVID-19, regardless of baseline risk for severe disease, during the SARS-CoV-2 Omicron JN.1-/KP.3-dominant epidemic era.

METHODS:

This nationwide, multi-institutional (51 acute-care hospitals in Japan), prospective, registry-based cohort study enrolled outpatients aged ≥12 years with laboratory-confirmed COVID-19 within 5 days of symptom onset (February 1-October 31, 2024). Participants were compared between those with and without oral antiviral use at enrollment (ensitrelvir, nirmatrelvir, or molnupiravir) for medical re-consultation, failure to return to usual health, and work productivity and activity impairment through Day 28. Analyses were conducted among participants with complete baseline covariates and valid Day 28 outcome assessments and were adjusted for pre-specified baseline covariates.

RESULTS:

Baseline characteristics were generally comparable between groups (efficacy analysis population: antiviral n=2271; no antiviral n=5768). Overall re-consultation rates tended to be lower in the antiviral group (adjusted risk ratio [aRR] 0.93; 95% CI 0.83-1.04). Antiviral use was associated with lower rates of failure to return to usual health (aRR 0.76; 95% CI 0.70-0.82) and with improvements in presenteeism, overall work impairment, and activity impairment.

CONCLUSIONS:

Early-phase oral antiviral use was associated with more favorable patient-reported and functional recovery outcomes, with a trend toward reduced healthcare utilization. These findings may have broader societal implications beyond traditional virological and disease progression endpoints.

2026-05-01·Clinical Drug Investigation

Effects of Ensitrelvir on the Pharmacokinetics of Combined Oral Contraceptives (Ethinyl Estradiol/Drospirenone) in Healthy Adult Women: A Phase 1 Fixed-Sequence, Multiple-Dose, Drug–Drug Interaction Study

Article

作者: Sonoyama, Takuhiro ; Okuda, Sho ; Kubota, Ryuji ; Shibata, Risa Yokokawa ; Shimizu, Ryosuke

BACKGROUND AND OBJECTIVE:

Ensitrelvir has shown cytochrome P450 3A (CYP3A) inhibitory/induction potential in in vitro studies. This open-label, fixed-sequence Phase 1 study evaluated potential drug-drug interactions between ensitrelvir and a combined oral contraceptive (COC) containing ethinyl estradiol (EE) and drospirenone in healthy women of childbearing age.

METHODS:

Healthy premenopausal women received EE/drospirenone (0.02 mg/3 mg) on days 1-24. Ensitrelvir was co-administered on day 20 (375 mg) and days 21-24 (125 mg/day). Blood samples were collected on days 19, 20, and 24 to assess plasma EE, drospirenone, and ensitrelvir concentrations. The primary endpoint was evaluation of the maximum plasma concentration, time to maximum plasma concentration, and area under the plasma concentration-time curve over the dosing interval τ (AUC_0-τ) assessed using noncompartmental methods. Treatment-emergent adverse events (TEAEs) were recorded for safety assessments.

RESULTS:

The safety and pharmacokinetic parameter population comprised 24 and 23 participants, respectively. Compared with day 19, AUC_0-τ ratios on days 20 and 24 were 1.02- and 1.07-fold for EE and 1.10- and 1.80-fold for drospirenone, respectively. This result suggested the inhibitory potential for CYP3A to be likely weaker on the first day than on the last day. Ensitrelvir AUC_0-τ was higher on day 24 versus day 20 and comparable with that reported previously. Treatment-emergent adverse events occurred in 58.3% of participants, none of which were severe, serious, or led to treatment discontinuation.

CONCLUSION:

Ensitrelvir has no clinically meaningful effect on the pharmacokinetics of EE and drospirenone, and the combination was well tolerated. These findings support the co-administration of ensitrelvir with COCs in clinical practice.

TRIAL REGISTRATION:

NCT06775730.

194

项与恩赛特韦相关的新闻（医药）

2026-05-14

·今日头条

首款新冠事后预防药获批！暴露后72小时吃，大幅降低感染风险！

你敢信吗？新冠疫情已经淡出大众视野多年，却突然传来一个足以改写防疫史的重磅消息：全球首款、真正能在接触病毒后预防新冠的口服药，正式来了！ 2026年5月13日，国际顶级期刊《新英格兰医学杂志》发表了一项里程碑式研究：日本盐野义制药研发的抗病毒药ensitrelvir（商品名Xocova），首次在临床试验中证明——和新冠感染者同住、近距离暴露后，只要72小时内服药，就能显著降低感染概率！这不是普通的治疗药，而是暴露后预防药！简单说：家里有人阳了、密接了，赶紧吃这个药，就能大概率不被传染！消息一出，全网沸腾！无数网友直呼：“早几年有这个，多少家庭不用隔离、多少老人能躲过一劫！” 更有专家直言：这是后疫情时代，给脆弱人群最硬核的生命保障！一、后疫情时代，最危险的人，一直没被真正保护很多人觉得：新冠早就“大号流感”了，没必要紧张。但事实是——对老人、有基础病、免疫力低下的人来说，新冠依然致命！养老院老人、器官移植患者、长期吃免疫抑制剂的人、癌症放化疗人群……他们一旦感染新冠，重症、死亡风险远超常人。疫情高峰过后，病毒虽然变弱，但对这些人而言，一次密接，就是一次生死考验！过去几年，我们有疫苗、有治疗药，但唯独缺一款简单、安全、口服、能事后预防的药。辉瑞的Paxlovid（奈玛特韦/利托那韦）曾被寄予厚望，也能治疗新冠，但在家庭暴露预防试验中失败了——效果不达标，没法作为预防药。其他抗病毒药、抗体药物也纷纷折戟，尤其是奥密克戎出现后，几乎所有预防手段都失效了。很长一段时间里，医学界陷入绝望：难道面对新冠密接，我们只能听天由命？直到**ensitrelvir（Xocova）**的出现，打破了僵局！二、硬核数据：密接后吃药，感染率直接砍半！这款药有多牛？看数据就懂，完全经得起推敲！国际大型临床试验，覆盖2000多名新冠家庭密接者，从2023年6月做到2024年9月，结果发表在《新英格兰医学杂志》，全球公认的顶级医学证据！试验规则：家里有人出现新冠症状后，72小时内，密接者要么吃5天ensitrelvir，要么吃安慰剂（无效药片）。结果震撼所有人： - 有症状感染率：安慰剂组9% → 吃药组3%，风险直接降了67%！ - 总感染率（含无症状）：安慰剂组21.5% → 吃药组14%，风险降低35%！简单说：100个密接者里，不吃药有9个会发病，吃药只剩3个；21个会感染，吃药只剩14个！这不是“心理安慰”，是实打实、统计学显著的预防效果！《新英格兰医学杂志》审稿专家直言：这是新冠药物研发史上，首次真正意义上的暴露后预防口服药成功！三、碾压Paxlovid！副作用更少、适用人群更广很多人会问：Paxlovid不是也能治新冠吗？为什么不能预防？关键区别：靶点相似，但效果天差地别！ ensitrelvir和Paxlovid里的奈玛特韦，靶点都是新冠病毒的3CL蛋白酶——阻止病毒复制。但在预防试验里： - Paxlovid：感染率只降30%，效果不达标，不能当预防药； - ensitrelvir：感染率降67%，效果达标，直接获批预防用途！更重要的是：ensitrelvir副作用远优于Paxlovid！ - Paxlovid：超半数人会有强烈金属味、恶心、腹泻，俗称“苦到怀疑人生”； - ensitrelvir：几乎无特殊异味，副作用和安慰剂差不多，耐受性极好！这意味着：老人、肝肾不好、体弱的人，也能安心吃！四、日本率先获批，欧美跟进！离我们还有多远？ 2026年3月，日本厚生劳动省率先批准ensitrelvir（Xocova）用于新冠暴露后预防——全球首个官方认证的新冠预防口服药！目前，美国、欧盟监管机构正在加急审批，美国预计1个月内出结果，大概率会通过！很多人关心：中国什么时候能用上？目前国内暂无获批消息，但专家普遍认为：这款药对脆弱人群价值巨大，后续大概率会加速引进或开展国内试验！毕竟，对中国庞大的老年人群、基础病人群而言，一款安全、有效的事后预防药，就是救命药！五、谁最需要这款药？这几类人务必重点关注不是所有人都需要囤药，但以下人群，密接后一定要优先考虑用药： 1. 65岁以上老人：年龄越大，重症风险越高； 2. 有基础病人群：高血压、糖尿病、心脏病、慢阻肺、肾病等； 3. 免疫力低下人群：器官移植、艾滋病、长期吃激素/免疫抑制剂、癌症放化疗； 4. 孕妇、婴幼儿：感染后风险更高； 5. 养老院、养老机构人员：聚集性感染风险高。一句话：健康年轻人密接后，大概率没事；但脆弱人群密接后，一定要抓住72小时黄金期！六、理性看待：不是“神药”，但绝对是“刚需药” 最后必须说清楚：ensitrelvir不是万能的，不能替代疫苗，也不能100%预防感染！ - 它是预防药，不是治疗药，越早吃效果越好，最好72小时内； - 不能替代口罩、勤洗手、通风等基础防护； - 健康人群没必要囤药，留给真正需要的脆弱人群。但不可否认：这是后疫情时代，人类对抗新冠的重要里程碑！从疫苗预防，到早期治疗，再到暴露后预防，我们终于补上了最后一块防疫拼图！对无数老人、脆弱人群而言，这款药不是冰冷的药片，而是面对病毒时，一份实实在在的安全感！未来，随着这款药在全球普及，或许我们再也不用怕“家里有人阳了”，再也不用眼睁睁看着脆弱亲人冒险——科技，终于为生命筑起了一道新防线！

2026-05-14

·BioSpace

New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure

SCORPIO-PEP is the first and only Phase 3 study of an oral antiviral to meet the primary endpoint of preventing symptomatic COVID-19 following exposure to an infected individual* Ensitrelvir is an investigational oral antiviral that could offer a new approach to preventing COVID-19 by blocking viral replication during the critical window between exposure and COVID-19 symptom onset Ensitrelvir is under review by FDA for post-exposure prophylaxis (PEP) of COVID-19, with a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2026 OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, were published in the New England Journal of Medicine . A five-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 by 67% in individuals following exposure to an infected individual through Day 10 compared to placebo. 1 Among participants in the primary analysis population (n=2,041) who received ensitrelvir, 2.9% developed symptomatic COVID-19, compared to 9.0% of those who received placebo through Day 10 (risk ratio: 0.33; 95% confidence interval [CI]: 0.22-0.49; p<0.0001). 1,2 In a prespecified subgroup analysis of participants with one or more risk factors for severe disease, a 76% reduction in relative risk for symptomatic COVID-19 was observed with ensitrelvir through Day 10, compared to placebo. 1 In this subgroup, 2.4% of participants who received ensitrelvir (9/382) developed symptomatic COVID-19 compared to 9.9% who received placebo (37/374) (risk ratio: 0.24; 95% CI: 0.12-0.49). 1 “Ensitrelvir works to inhibit viral replication, helping protect people who have been exposed to COVID-19 from becoming sick. In this study, people taking ensitrelvir within 72 hours after household exposure were three times less likely to develop COVID-19 compared with those given placebo,” said Frederick Hayden, MD, Professor Emeritus of Clinical Virology and Professor Emeritus of Medicine, University of Virginia School of Medicine. “These first, clearly positive results with an oral antiviral underscore ensitrelvir’s potential to protect a range of individuals from COVID-19, including those at higher risk of severe disease and potentially in other settings.” In the SCORPIO-PEP study, ensitrelvir was generally well tolerated, with similar rates of adverse events across groups (15.1% in the ensitrelvir group (n=1,190) and 15.5% in the placebo group (n=1,187)). 1 The most common treatment-emergent adverse events (greater than or equal to 1%) were headache, diarrhea, nasopharyngitis, cough, fatigue and influenza. 3 There were no reports of altered taste (dysgeusia) attributed to ensitrelvir in the trial. 1 Future SARS-CoV-2 transmission and impact are unpredictable, with the potential for surges and emergence of new variants, such as the heavily mutated Omicron subvariant BA.3.2, nicknamed “Cicada” now circulating in at least 25 U.S. states. 4,5,6,7 COVID-19 can become severe, and even if mild or moderate, it can exacerbate or worsen chronic conditions or lead to the onset of new ones, including long COVID. 8,9,10,11,12 Following exposure to COVID-19, an effective way to avoid its potentially serious and long-term complications is to block viral replication, which helps prevent the development of the disease. 13,14,15,16 There are currently no approved therapies to help prevent COVID-19 following exposure. 17,18 Other COVID-19 antivirals approved for treatment are taken after illness has developed and the immune cascade has begun. 19 “Ensitrelvir offers a potential new approach to help prevent COVID-19 after exposure. By preventing COVID-19, people can avoid not only potentially serious consequences of acute disease, but also the risk of exacerbating pre-existing conditions or acquiring new conditions, such as long COVID. Ensitrelvir cuts the chances of developing COVID-19 by two-thirds, which is substantial, particularly in households where the risk of spread is high,” said Aeron Hurt, PhD, Vice President, Global Medical Science, Shionogi. “Shionogi’s deep expertise in antivirals has changed the way we treat and prevent other viral infections, including influenza and HIV, and there is an opportunity to do the same with COVID-19. Ensitrelvir has the potential to be the first oral antiviral to help prevent COVID-19 after exposure.” About SCORPIO-PEP The global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, assessed the safety and efficacy of ensitrelvir as post-exposure prophylaxis. The study included 2,387 study participants aged 12 years and older with a negative local screening test for SARS-CoV-2 infection and no symptoms at the time of enrollment, who were exposed to a person living in their household with symptomatic COVID-19. The primary analysis included 2,041 household contact participants with a central laboratory-confirmed negative SARS-CoV-2 test. The trial was conducted from June 2023–September 2024. More than 98% of household contacts tested positive for SARS-CoV-2 N and/or S antibodies, indicating that nearly all had evidence previous SARS-CoV-2 infection or vaccination, or both. Study participants were randomly assigned at a 1:1 ratio to receive ensitrelvir (375 mg on day 1 and 125 mg on days 2-5) or placebo, once daily, and began treatment within 72 hours of when the household member with COVID-19 (index patient) began showing symptoms. Participants then continued ensitrelvir (125 mg) or placebo for five days. SCORPIO-PEP is the first and only Phase 3 study of an oral antiviral to meet the primary endpoint of preventing COVID-19 following exposure to an infected individual. About ensitrelvir Ensitrelvir is a SARS-CoV-2 main protease inhibitor created through joint research between Hokkaido University and Shionogi. SARS-CoV-2 has an enzyme called the main protease, which is essential for the replication of the virus. Ensitrelvir suppresses the replication of SARS-CoV-2 by selectively inhibiting the main protease. Ensitrelvir is under review by the U.S. FDA for post-exposure prophylaxis (PEP) of COVID-19, with a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2026. Ensitrelvir, known as XOCOVA® in Japan, received emergency regulatory approval in Japan in November 2022 and full approval in March 2024 for the treatment of COVID-19 based on results from SCORPIO-SR, a Phase 3 study conducted in Asia, during the Omicron-dominant phase of the pandemic. Results from this study were published in JAMA Network Open . In 2025, Shionogi submitted a supplemental New Drug Application for COVID-19 treatment in pediatric patients aged 6 to under 12 years in Japan. In March 2026, XOCOVA received approval in Japan for the prevention of COVID-19 following exposure . Ensitrelvir is currently under regulatory review in Taiwan for post-exposure prophylaxis of COVID-19. Ensitrelvir is an investigational drug outside of Japan. In addition, the brand name XOCOVA has not been approved for use outside of Japan and pertains only to the approved drug in Japan. About Shionogi & Co., Ltd. Shionogi & Co., Ltd. is a 148-year-old global, research-driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders and cardiovascular diseases. Shionogi’s research and development currently targets two therapeutic areas: infectious diseases and diseases with unmet medical needs in pain/CNS, including Alzheimer’s disease, oncology, rare diseases, and sleep apnea. For more information on Shionogi & Co., Ltd., please visit . Forward-Looking Statements This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. *Literature search conducted March 2026. References: 1 Hayden FG, Shinkai M, Clark TW, et al. Ensitrelvir COVID-19 Post-exposure Prophylaxis in Household Contacts. N Eng J Med . 2026;383(19):1905- 1915 . 2 Hayden FG, Shinkai M, Clark TW, et al. Supplementary Appendix. Ensitrelvir COVID-19 Post-exposure Prophylaxis in Household Contacts. Supplementary Appendix. N Eng J Med . 2026;383(19) 3 Hayden FG, Ohmagari N, et.al. Ensitrelvir for the prevention of COVID-19 among household contacts: Key subgroup analyses of SCORPIO-PEP phase 3 study. Abstract 03159. Presented at Congress of the European Society of Clinical Microbiology and Infectious Diseases 2026. . 4 Jalal H, Lee K, Burke DS. Oscillating spatiotemporal patterns of COVID-19 in the United States. Sci Rep. 16 Sept 2024;(14):21562. DOI: 10.1038/s41598-024-72517-6 . 5 Rose EB, Paden CR, et al. Estimated COVID-19 periodicity and correlation with SARS-CoV-2 spike protein S1 antigenic diversity, United States. Emerg Infect Dis . 2025;31(8):1573–1579. DOI: 10.3201/eid3108.250451 . 6 Centers for Disease Control and Prevention. Early Detection and Surveillance of the SARS-CoV-2 Variant BA.3.2 — Worldwide, November 2024–February 2026. Morbidity and Mortality Weekly Report . 2026;75(10):130-137. DOI: 10.15585/mmwr.mm7510a1 . 7 Rubin, R. What to know about Cicada, or BA.3.2, the latest SARS-CoV-2 variant under monitoring. JAMA . 17 Apr 2026. DOI: 10.1001/jama.2026.5535 8 Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med . 7 Feb 2022;28(3): 583–590. DOI: 10.1038/s41591-022-01689-3 . 9 Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with COVID-19: cohort study. BMJ . 16 Feb 2022;376:e068993. DOI: 10.1136/bmj-2021-068993 . 10 Srivastava S, Garg I. Post-COVID-19 infection: Long-term effects on liver and kidneys. World J Meta-Anal . 28 Jun 2021;9(3):220–233. DOI: 10.13105/wjma.v9.i3.220 . 11 Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March–June 2020. Morbidity and Mortality Weekly Report . 31 Jul 2020;69(30):993–998. DOI: 10.15585/mmwr.mm6930e1 . 12 Graham EL, Clark JR, Orban ZS, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized COVID-19 “long haulers.” Ann Clin Trans Neurol . 23 Mar 2021;8(5):1073–1085. DOI: 10.1002/acn3.51350 . 13 Centers for Disease Control and Prevention. Preliminary estimates of COVID-19 burden for 2024–2025. 6 Feb 2026. Available at: . 14 World Health Organization. Post COVID-19 condition (Long COVID). 7 Dec 2022. Available at: . 15 Al-Aly Z, Davis HE, McCorkell L, et al. Long COVID science, research and policy. Nat Med . 9 Aug 2024;30(8):2148–2164. DOI: 10.1038/s41591-024-03173-6 . 16 Al-Aly Z, Topol E. Solving the puzzle of long COVID. Sci . 22 Feb 2024;383(6685):830–832. DOI: 10.1126/science.adl0867 . 17 U.S. Food and Drug Administration. FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19. 2021. Available at: . 18 U.S. Food and Drug Administration. Revocation of emergency use of a drug product during the COVID-19 pandemic; availability. Federal Register . 2024. Available at: . 19 Centers for Disease Control and Prevention. COVID-19 treatments and medications . 2023. Available at: . Contacts For Further Information: U.S. Media: ShionogiCommunications@shionogi.com SHIONOGI Website Inquiry Form: Shionogi Europe Press Office: pressoffice@shionogi.eu

临床结果临床3期上市批准

2026-05-13

·北京医学感染与传染研究

感染性疾病与治疗 15卷 1-5期

Infectious Diseases and Therapy Volume 15, Issue 1 感染性疾病与治疗 15卷 1期 https://link.springer.com/journal/40121/volumes-and-issues/15-1 Review（综述） 1 How to Better Screen for Blood-Borne Viruses, Specifically HIV, in Hospital Emergency Departments: French and European Perspectives 医院急诊科如何更好地筛查血源性病毒（尤其是HIV）：法国和欧洲视角 Anthony Romain ChauvinBruno George SpireOlivier Bouchaud Pages: 1 - 18 2 Understanding the Epidemiology and Contributing Factors of Post-COVID-19 Pertussis Outbreaks: A Narrative Review 了解新冠疫情后百日咳爆发的流行病学及影响因素：叙述性综述 Juan C. Vargas-ZambranoSorin AbrudanDenis Macina Pages: 19 - 41 Part of 1 collection: Digital Features - Infectious Diseases 所属专题集：数字专题 - 传染病 3 The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review 康替唑胺抗结核的结构、特性及临床应用价值：叙述性综述 Tao ChenWeili LiFan Wu Pages: 43 - 56 4 A Review of Doxycycline Post-Exposure Prophylaxis and Its Implications for Antimicrobial Resistance and the Human Microbiome 综述：多西环素暴露后预防用药及其对抗菌药物耐药性和人体微生物组的影响 Ruben Fernandez-IbanezSantiago MorenoMoises Fernandez Pages: 57 - 84 Original Research（论著） 5 Clinical Impact of Implementing a Specific Clinical Pathway for the Management of Clostridioides difficile Infection 实施特定临床方法治疗艰难梭菌感染的临床影响 Miguel Rodríguez-FernándezRocio HerreroNicolás Merchante Pages: 85 - 100 6 Intensive Care Unit Stay and Mechanical Ventilation Among Adults with Respiratory Syncytial Virus-Related Hospitalization by Age and Comorbidity Status 按年龄和合并症状况划分的呼吸道合胞病毒相关住院成人患者的重症监护病房住院时间和机械通气情况 Caihua LiangYun ZhouElizabeth Begier Pages: 101 - 115 7 Treatment Persistence and Switch Among Medicare-Insured People with HIV and Gaps in Care 医疗保险覆盖的HIV感染者治疗坚持情况、用药转换情况及护理缺口 Suying LiUche MordiPhyllis C. Tien Pages: 117 - 132 8 High-Dose Minocycline Improves Outcomes in Acinetobacter baumannii Group Pneumonia: A Propensity-Weighted Cohort Study with MIC-Based Insights for Breakpoint Revision 大剂量米诺环素可改善鲍曼不动杆菌群肺炎的预后：一项基于倾向加权队列的研究，并基于最低抑菌浓度提出折点修订见解 Yu-Tao TsengYang-Chuan ChenYung-Chih Wang Pages: 133 - 148 9 Post-cranial Neurosurgery Cutibacterium acnes Infections: Clinical Correlates, Presentation, and Outcomes—A Matched Case–Case–Control Study 颅脑神经外科术后皮肤杆菌属感染：临床相关性、表现及预后——一项匹配病例-病例-对照研究 Neta ShirinOfek ArvivIli Margalit Pages: 149 - 164 10 Bone Mineral Density Changes in People with HIV Who had Immediate Switch Versus Deferred Switch from Tenofovir Disoproxil Fumarate-Based Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Multicenter, Open-Label, Randomized Clinical Trial 从基于富马酸替诺福韦二吡呋酯的方案立即转换与延迟转换为比克替拉韦/恩曲他滨/丙酚替诺福韦的HIV感染者骨密度变化：一项多中心、开放标签、随机临床试验 Yueming ShaoXinping YangJun Chen Pages: 165 - 181 11 Microbiological, Clinical, and Pharmacokinetic/Pharmacodynamic Data to Support EUCAST Aztreonam–Avibactam Minimum Inhibitory Concentration Susceptibility Breakpoints Against Enterobacterales 支持欧洲抗微生物药物敏感性试验委员会（EUCAST）针对肠杆菌科细菌的氨曲南-阿维巴坦最低抑菌浓度敏感性折点的微生物学、临床及药代动力学/药效学数据 Susan R. RaberRujia XieJoseph W. Chow Pages: 183 - 195 12 Epidemiology of Invasive Escherichia coli Disease in Adults Using Routine Healthcare Records from the United States, 2002–2022 利用美国常规医疗记录（2002-2022年）分析成人侵袭性大肠杆菌病的流行病学特征 Mark A. SchmidtMaxim BlumJeroen Geurtsen Pages: 197 - 216 13 Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies 转换为比克替拉韦/恩曲他滨/丙酚替诺福韦的HIV感染者生活质量及治疗满意度：观察性队列研究的汇总分析 Andrea AntinoriYoshiyuki YokomakuMarta Boffito Pages: 217 - 244 14 Dual Transmission Dynamics of Carbapenem Resistance in Pediatric Oncology: Plasmid-Mediated and Clonal Spread of blaNDM-5 Enterobacterales 儿科肿瘤中碳青霉烯类耐药性的双重传播动态：blaNDM-5肠杆菌科的质粒介导与克隆传播 Deena JalalMaryam LotfiLobna Shalaby Pages: 245 - 263 Part of 1 collection:Digital Features - Infectious Diseases 所属专题集：数字专题 - 传染病 15 Cost-Effectiveness Analysis of Aztreonam–Avibactam Compared with Colistin Plus Meropenem in Treating Metallo-Beta-Lactamase-Producing Enterobacterales Infections in Spain 氨曲南-阿维巴坦与黏菌素联合美罗培南治疗西班牙产金属β-内酰胺酶肠杆菌科感染的成本效果分析 Gerardo AguilarPatricia Ruiz-GarbajosaJulián Torre-Cisneros Pages: 265 - 284 16 Synchronous anal HPV Infection in Patients with HPV-Related Gynaecological Diseases: A Prospective Study 人乳头瘤病毒（HPV）相关妇科疾病患者同步肛部HPV感染：一项前瞻性研究 Michał BrzezińskiMaciej Stukan Pages: 285 - 295 17 Growth in Anaerobic Bottles is an Independent Predictor of Mortality in Pseudomonas aeruginosa Bloodstream Infections 厌氧瓶中生长是铜绿假单胞菌血流感染死亡的独立预测因素 Daniel N. MarcoLaura MorataAlex Soriano Pages: 297 - 311 18 Acute and Long-Term Healthcare Utilization and Expenditures for Serious Bacterial Infections among Newborns in US Hospitals 美国医院新生儿严重细菌感染的急性和长期医疗资源利用及费用 Kristen N. NobleKatharina SchleyDerek Weycker Pages: 313 - 325 19 Impact of Risk Stacking on COVID-19–Related Healthcare Utilization: A Real-World Retrospective Cohort Study 风险叠加对新冠相关医疗资源利用的影响：一项现实回顾性队列研究 Frank R. ErnstLeah McGrathAlejandro Cané Pages: 327 - 343 20 Chest Computed Tomography Patterns Associated with Severity in Adults with Respiratory Syncytial Virus Infection: A Retrospective Cohort Study 成人呼吸道合胞病毒感染严重程度相关的胸部计算机断层扫描模式：一项回顾性队列研究 Marie Le GoffYoussef ZaarourNicolas de Prost Pages: 345 - 363 Case Series（病例系列） 21 Management and Resolution of Hypersensitivity Pneumonitis-Related Events in Japanese Patients Treated with Amikacin Liposome Inhalation Suspension in the CONVERT and INS-312 Clinical Trials 在CONVERT和INS-312临床试验中，接受硫酸阿米卡星脂质体吸入混悬液治疗的日本患者发生过敏性肺炎相关事件的管理与解决 Yoshitaka YamazakiTaku NakagawaNaoki Hasegawa Pages: 365 - 379 Letter（读者来信） 22 A Response to: Letter to the Editor Regarding “The Risk of Herpes Zoster in Patients with Depressive Disorders: A German Claims Database Analysis” 对《关于“抑郁障碍患者带状疱疹风险：一项德国索赔数据库分析”的来信》的回复 Pavo MarijicJulian WitteChristiane Hermann Pages: 381 - 383 23 Letter to the Editor Regarding“The Risk of Herpes Zoster in Patients with Depressive Disorders: A German Claims Database Analysis” 致编辑的信：关于“抑郁障碍患者带状疱疹风险：一项德国索赔数据库分析” Kuan-Fu LiaoShih-Wei Lai Pages: 385 - 386 Correction（更正） 24 Correction: Budget Impact Analysis of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) for Recurrent Clostridioides difficile Infection in the United States 更正：美国复发性艰难梭菌感染粪便微生物群孢子活菌brpk（原SER-109）的预算影响分析 Michele WilsonYoav GolanAlpesh N. Amin Pages: 387 - 387 25 Correction: A Response to: Letter to the Editor Regarding “The Risk of Herpes Zoster in Patients with Depressive Disorders: A German Claims Database Analysis” 更正：对《关于“抑郁障碍患者带状疱疹风险：一项德国索赔数据库分析”的来信》的回复 Pavo MarijicJulian WitteChristiane Hermann Pages: 389 – 389 Infectious Diseases and Therapy Volume 15, Issue 2 感染性疾病与治疗 15卷 2期 https://link.springer.com/journal/40121/volumes-and-issues/15-2 Review（综述） 1 HepatitisA to E in People with HIV: A Virus-Specific Review of Prevention and Treatment HIV感染者中的甲型至戊型肝炎：针对不同病毒的预防和治疗综述 Kuan-Yin LinYi-Chia HuangChien-Ching Hung Pages: 391 - 415 2 The Cefazolin Inoculum Effect: An Underappreciated Factor in MSSA Treatment Strategies 头孢唑林接种物效应：甲氧西林敏感金黄色葡萄球菌治疗策略中一个未被充分重视的因素 Prakhar SrivastavaElizabeth SingletonRazieh Kebriaei Pages: 417 - 441 3 Meningococcal Disease in Older Adults: Challenges in Diagnosis and Management 老年人群中的脑膜炎球菌病：诊断与治疗的挑战 Muhamed-Kheir TahaCatherine Weil-OlivierSaber Yezli Pages: 443 - 459 4 The Future of Antibiotics and Artificial Intelligence: Some Thoughts from Discovery to Bedside 抗生素与人工智能的未来：从发现到临床应用的一些思考 Daniele Roberto GiacobbeAlessandra Agnese GrossiCesar de la Fuente-Nunez Pages: 461 - 475 Original Research（论著） 5 Estimating the Health and Economic Burden of Pneumococcal Diseases Attributable to PCV21 Versus PCV20 or PPSV23 Serotypes Among Adults in Norway 挪威成年人中PCV21与PCV20或PPSV23血清型所致肺炎球菌疾病的健康和经济负担估算 Zinan YiAthar Ali TajikKwame Owusu-Edusei Pages: 477 - 490 6 Seven versus Fourteen Days of Antibiotics for Gram-Negative Bacteremia from a Urinary Tract Source: a Systematic Review and Meta-analysis 尿路感染来源的革兰阴性菌血症抗生素治疗7天与14天的系统综述和荟萃分析 Graciela LunaAndrea RodriguezMichael Sabina Pages: 491 - 505 7 Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Causing Healthcare-Associated Bloodstream Infections in Brazil: Results from A Prospective Countrywide Multicenter Study 巴西医疗保健相关血流感染中耐甲氧西林金黄色葡萄球菌的分子流行病学：一项前瞻性全国多中心研究的结果 Laura C. AntochevisLetícia O. SudbrackAlexandre P. Zavascki Pages: 507 - 525 8 Long-Term Antibody Persistence After Hepatitis A Vaccination in Healthy Toddlers: Insights from Modeling 健康幼儿接种甲型肝炎疫苗后长期抗体持久性：基于模型的见解 Carlos EspulHéctor Horacio CuelloLaurent Coudeville Pages: 527 - 538 9 Prevalence of Respiratory Syncytial Virus in Adult Patients with Respiratory Illnesses in Low to Middle-Income Countries: A Systematic Review and Meta-Analyses 中低收入国家成人呼吸道疾病患者中呼吸道合胞病毒的流行率：一项系统综述和荟萃分析 Digant GuptaAmandeep KaurAdriana Guzman-Holst Pages: 539 - 559 10 Novel Diagnostic Marker Interleukin-33 for Invasive Pulmonary Aspergillosis in Acute-on-Chronic Liver Failure: A Proof-of-Concept Prospective Study 慢加急性肝衰竭合并侵袭性肺曲霉病的新型诊断标志物白细胞介素-33：一项概念验证前瞻性研究 Lanyue HuangMeng ZhangQin Ning Pages: 561 - 576 11 Testing the Feasibility of a Self-Help Intervention That Includes Lymphatic Drainage to Reduce Fatigue-Related Symptoms Among Patients with Long COVID in General Practice: Experiences from Our Randomized Controlled Trial (RCT) 在全科医疗中测试包含淋巴引流以减轻长期新冠患者疲劳相关症状的自助干预措施的可行性：我们的随机对照试验（RCT）经验 Lisa RisteRaymond PerrinAdrian Heald Pages: 577 - 589 12 Comparative Diagnostic Performance of the 36-Minute STANDARD M10 Fast Assay for Molecular Diagnosis of SARS-CoV-2, InfluenzaA and B, and Respiratory Syncytial Virus in Near-Patient Settings 36分钟STANDARD M10快速检测法在床旁检测中对SARS-CoV-2、甲型和乙型流感病毒以及呼吸道合胞病毒的分子诊断性能比较 Alexander DomnichGiada GarzilloGiancarlo Icardi Pages: 591 - 604 13 Clinical Phenotypes of Critically Ill Patients with COVID-19 Infected with Omicron: A Nationwide Prospective Cohort Study 感染奥密克戎的危重症COVID-19患者的临床表型：一项全国性前瞻性队列研究 Etienne AudureauPierre Baythe SEVARVIR investigators Pages: 605 - 628 Brief Report（简报） 14 How do Recent Population-Level RSVpreF Vaccine-Impact Results from the United Kingdom Relate to Previously Reported Vaccine Effectiveness Results? 英国最近公布的RSVpreF疫苗在人群层面的影响结果与之前报告的疫苗有效性结果有何关联？ Negar AliabadiQing LiuElizabeth Begier Pages: 629 - 637 Case Report（病例报告） 15 Continuous Infusion of Aztreonam–Avibactam After High Loading Dose for an Infection Caused by an OXA-48- and NDM-1-Co-producing ST147 Klebsiella pneumoniae 针对OXA-48和NDM-1共产生的ST147型肺炎克雷伯菌感染，采用高负荷剂量后持续输注氨曲南-阿维巴坦 Paul Laffont-LozesFanny VillaRomaric Larcher Pages: 639 - 649 Infectious Diseases and Therapy Volume 15, Issue 3 感染性疾病与治疗 15卷3期 https://link.springer.com/journal/40121/volumes-and-issues/15-3 Commentary（述评） 1 Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease 预防婴儿呼吸道合胞病毒疾病中孕妇接种疫苗的全面健康及社会价值的分类学研究 J. P. SevillaDaria BurnesDavid E. Bloom Pages: 651 - 682 Original Research（论著） 2 Characteristics of Haemophilus influenzae Isolates Responsible for Invasive Infections in Poland in 2018–2023 2018-2023年波兰引起侵袭性感染的流感嗜血杆菌分离株的特征 Marlena KiedrowskaKinga BłaszczykAnna Skoczyńska Pages: 683 - 700 3 Evaluating the Effectiveness of 2024–2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Related Hospitalizations and Medically Attended COVID-19 Among Adults Aged ≥ 18 years in the United States: An Observational Matched Cohort Study 评估2024-2025年季节性mRNA-1273疫苗对美国≥18岁成年人预防与COVID-19相关住院和就医的效力：一项观察性匹配队列研究 Nevena VicicAlina BogdanovAmanda Wilson Pages: 701 - 714 4 Elevated Plasma GDF-15 Levels Are Associated with Aging, Multimorbidity, and Tobacco Exposure in People with HIV HIV感染者中血浆GDF-15水平升高与衰老、多种合并症及烟草暴露相关 Aida López LópezJacobo Alonso DomínguezCoRIS Cohort Pages: 715 - 731 5 High Burden of Febrile Sub-microscopic Plasmodium Mixed Infections in Central India: A Cross-Sectional Study 印度中部无症状疟原虫混合感染伴发热疾病负担高：一项横断面研究 Nimita DeoraVeena PandeAbhinav Sinha Pages: 733 - 747 6 How Status Quo Bias Shapes Willingness, Uptake, and Adherence to PrEP Among Chinese MSM: A Behavioral Economics Perspective 从行为经济学视角看现状偏见如何影响中国男男性行为者对暴露前预防的意愿、接受度和依从性 Min ZhaoXiang ZhaoLei Zhang Pages: 749 - 767 7 Immunogenicity and Safety of Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Potential Hajj/Umrah Pilgrims Aged≥56 Years: A Phase III, Open-Label Study 四价脑膜炎球菌结合疫苗（MenACYW-TT）在≥56岁潜在朝觐/副朝觐者中的免疫原性和安全性：一项III期、开放标签研究 Ghassan S. DbaiboIsmail BalikMehmet Ceyhan Pages: 769 - 785 Part of 1 collection: Digital Features - Infectious Diseases 所属合集：数字专题 -传染病 8 Clinical Impact of Droplet Digital PCR-Guided Antibiotic Stewardship on Prognosis in Patients with Suspected Bloodstream Infection: A Prospective Observational Study 液滴数字PCR指导的抗生素管理对患者疑似血流感染预后的临床影响：一项前瞻性观察研究 Ziqiang ShaoJingwen ZhuBangchuan Hu Pages: 787 - 807 9 Outpatient RSV Testing Rates Among US Adults with Lower Respiratory Tract Disease, 2017–2024 2017-2024年美国下呼吸道疾病成人患者门诊呼吸道合胞病毒检测率 Katherine K. PerezKashmira DateElizabeth Begier Pages: 809 - 834 10 Role of Cefiderocol in the Treatment of Carbapenem-Resistant Nonfermenting Gram-Negative Bacilli (Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia) Infections: An Expert Statement 头孢地尔在治疗碳青霉烯类耐药非发酵革兰氏阴性杆菌（鲍曼不动杆菌、铜绿假单胞菌和嗜麦芽窄食单胞菌）感染中的作用：专家声明 Alexandre BleibtreuYoussef BennisCoRIS Cohort Pages: 835 - 857 11 IgG4 Neutralization and Sustained Total IgG Fc-Effector Functions Following Repeated SARS-CoV-2 Vaccination with mRNA-1273 重复接种mRNA-1273疫苗后IgG4中和作用及总IgG Fc效应功能的持续存在 Paulina KaplonekHarry BerteraCarole Henry Pages: 859 - 874 12 Rising Burden of Herpes Zoster among General Adults and Increased-Risk Groups in Eastern China, 2015–2021: A Population-Based Cohort Study 2015-2021年中国东部普通成人及高风险人群带状疱疹负担上升：一项基于人群的队列研究 Zhenwei LiShenjia GuChuanxi Fu Pages: 875 - 888 13 Safety and Efficacy of Fecal Microbiota, Live-jslm for Prevention of Recurrent Clostridioides difficile Infection Among Hospitalized Participants in PUNCH CD3-OLS PUNCH CD3-OLS研究中住院患者使用活菌粪便微生物群（Live-jslm）预防复发性艰难梭菌感染的安全性和有效性 Andrew M. SkinnerThomas P. LodiseJordan E. Axelrad Pages: 889 - 901 Letter（读者来信） 14 Letter to the Editor Regarding “Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States” 致编辑的信：关于“美国HIV和乙型肝炎病毒合并感染者启动抗逆转录病毒治疗后发生晚期肝病事件” Keiji Konishi Pages: 903 - 905 15 A Response to: Letter to the Editor Regarding “Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States” 回复：致编辑的信——关于“美国HIV和乙型肝炎病毒合并感染者启动抗逆转录病毒治疗后发生晚期肝病事件” Ching-Yi ChuoWoodie ZachryLi Tao Pages: 907 - 909 16 A Response to: “Letter to the Editor regarding ‘Impact of Continuous Renal Replacement Therapy with Polyacrylonitrile-Derived Filter on Caspofungin Concentration: A Retrospective Study'” 回复：致编辑的信——关于“聚丙烯腈衍生滤器连续性肾脏替代治疗对卡泊芬净浓度的影响：一项回顾性研究” Romain ArrestierKeyvan Razazi Pages: 911 - 914 17 Letter to the Editor regarding 'Impact of Continuous Renal Replacement Therapy with Polyacrylonitrile-Derived Filter on Caspofungin Concentration: A Retrospective Study' 致编辑的信——关于“聚丙烯腈衍生滤器连续性肾脏替代治疗对卡泊芬净浓度的影响：一项回顾性研究” Julien MassolValentin MauletFrédéric J. Baud Pages: 915 - 919 Infectious Diseases and Therapy Volume 15, Issue 4 感染性疾病与治疗 15卷 4期 https://link.springer.com/journal/40121/volumes-and-issues/15-4 Review（综述） 1 Outpatient Parenteral Antimicrobial Therapy (OPAT) in Italy: A Scoping Review 意大利门诊静脉注射抗菌药物治疗（OPAT）：一项范围综述 Chiara MorealSimone GiulianoCarlo Tascini Pages: 921 - 939 2 Reimagining Phage Therapy for MDR Pathogens: From Biobanks to Health System Integration—A Review 重新构想噬菌体疗法治疗多重耐药病原体：从生物银行到卫生系统整合——综述 Abay A. AyeleWenfeng LiuAbel A. Negash Pages: 941 - 957 3 Navigating the Viral Hepatitis Drug Landscape: New Discoveries and Enduring Challenges. A Narrative Review 探索病毒性肝炎药物领域：新发现与持久挑战。一篇叙述性综述 He-ming SunXing-yu WangYan-hang Gao Pages: 959 - 985 Original Research（论著） 4 Predictive Utility of the Pediatric-EQUAL Scale in Pediatric Candidemia Admitted to PICU Association with Clinical and Microbiological Factors Related Mortality 儿科-EQUAL量表对入住PICU的念珠菌血症患儿的预测效用：与临床和微生物学因素相关死亡率的关联 Muhterem DuyuAyşe Aşık Pages: 987 - 1001 Publisher Correction（出版商更正） 5 Publisher Correction: Predictive Utility of the Pediatric-EQUAL Scale in Pediatric Candidemia Admitted to PICU Association with Clinical and Microbiological Factors Related Mortality 出版商更正：儿科-EQUAL量表对入住PICU的念珠菌血症患儿的预测效用：与临床和微生物学因素相关死亡率的关联 Muhterem DuyuAyşe Aşık Pages: 1003 - 1005 Original Research（论著） 6 A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19 用于从中和抗体滴度预测疗效以建立预防新冠肺炎单克隆抗体免疫桥接的统计免疫保护相关因素模型 Ilker YalcinLeijun HuMark A. Wingertzahn Pages: 1007 - 1017 7 Early Antibiotic Therapy in Sepsis Without Shock: A Multimethod Study of Heterogeneous Treatment Effects in ICU Patients 无休克性脓毒症的早期抗生素治疗：一项针对ICU患者异质性治疗效果的多方法研究 Peng ZhangTongkun ZuoYing Huang Pages: 1019 - 1033 8 Post-marketing Safety Surveillance of 23-Valent Pneumococcal Polysaccharide Vaccine Administered Alone and Concomitantly with Influenza Vaccine in Individuals Aged 2Years and Older in China 中国2岁及以上人群单独接种及与流感疫苗同时接种23价肺炎球菌多糖疫苗的上市后安全监测 Yun-feng ShiLin-hang JuHong-xing Pan Pages: 1035 - 1046 9 Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study 美国预防婴儿呼吸道合胞病毒下呼吸道感染：Nirsevimab和Clesrovimab的成本效益——一项建模研究 Benjamin YarnoffMatthieu BeuveletLeonard R. Krilov Pages: 1047 - 1073 10 Oritavancin in Complicated Bloodstream Infections and Endocarditis in Spain and Italy (ORIBAC Study): A Retrospective Multicenter Observational Study 西班牙和意大利奥利他万星治疗复杂血流感染和心内膜炎（ORIBAC研究）：一项回顾性多中心观察研究 Antonio VenaLaura MezzogoriORIBAC study group Pages: 1075 - 1092 11 Mitigating Vaccine Disparities Through Faith-Based Intervention: A Pre-Post Analysis of Recombinant Zoster Vaccine Knowledge and Acceptance in Socially Vulnerable Racial and Ethnic Minoritized Communities 通过基于信仰的干预措施减轻疫苗差异：对社会弱势的种族和少数民族群体重组带状疱疹疫苗认知和接受度的前后分析 Jacinda C. Abdul-MutakabbirRaheem Abdul-MutakabbirSamuel J. Casey Pages: 1093 - 1114 12 Epidemiological Burden and Hospitalization Trends of Human Metapneumovirus in Spain (2016–2023): A Retrospective Study 西班牙人类偏肺病毒的流行病学负担和住院趋势（2016 - 2023年）：一项回顾性研究 Oscar Brochado-KithRuth Gil-PrietoAngel Gil-de-Miguel Pages: 1115 - 1135 13 Using Real-World Data to Support Claim Expansion of the Cobas SARS-CoV-2 Test in Asymptomatic Testing: Data from the National Football League Occupational Surveillance Program 使用现实数据支持Cobas SARS-CoV-2检测在无症状检测中的适用范围扩大：来自美国国家橄榄球联盟职业监测计划的数据 Baiyu YangErin B. WassermanElodie Baumfeld Andre Pages: 1137 - 1148 Infectious Diseases and Therapy Volume 15, Issue 5 感染性疾病与治疗 15卷 5期 https://link.springer.com/journal/40121/volumes-and-issues/15-5 Review（综述） 1 Efficacy and Safety of Tetracyclines in Bone and Joint Infections: A Literature Review 四环素类药物治疗骨关节感染的有效性和安全性：文献综述 Paul Laffont-LozesRomaric LarcherAlbert Sotto Pages: 1149 - 1174 2 The Ongoing Challenge of Pertussis in Eastern and Northern Europe: Recommendations from the Global Pertussis Initiative 东欧和北欧百日咳持续存在的挑战：全球百日咳倡议的建议 Mine Durusu TanrioverUlrich HeiningerKevin Forsyth Pages: 1175 - 1201 3 Antibiotic Pharmacokinetics and Prostate Penetration in Bacterial Prostatitis: A Systematic Review 细菌性前列腺炎的抗生素药代动力学及前列腺穿透性：系统综述 Rui GeXinwen NianZhuo Wang Pages: 1203 - 1248 4 Treatment for Dientamoeba fragilis: A Systematic Review and Meta-analysis 脆弱双核阿米巴病的治疗：系统综述和荟萃分析 Nadav BaharavMichael ItzkovichDafna Yahav Pages: 1249 - 1262 Original Research（论著） 5 Preparing for Tuberculosis Vaccine M72/AS01E Implementation: A Global Demand Forecast and Key Influential Factors 结核病疫苗M72/AS01E实施准备工作：全球需求预测及关键影响因素 Judith KallenbergDominique MileaAgathe Philippot Pages: 1263 - 1279 Correction（更正） 6 Correction: Preparing for Tuberculosis Vaccine M72/AS01E Implementation: A Global Demand Forecast and Key Influential Factors 更正：结核病疫苗M72/AS01E实施准备工作：全球需求预测及关键影响因素 Judith KallenbergDominique MileaAgathe Philippot Pages: 1281 - 1281 Original Research（论著） 7 Impact of Nirsevimab on Pediatric RSV-Related Lower Respiratory Tract Infections: A Retrospective Pre–Post Observational Study in Tuscany, Italy 尼塞韦单抗对意大利托斯卡纳地区儿童呼吸道合胞病毒相关下呼吸道感染的影响：一项回顾性前后对照观察研究 Francesco NiedduMarta VerzieriMaria Moriondo Pages: 1283 - 1295 8 Antiretroviral Therapy Switching Among People with HIV in the United States is not Uncommon Despite Virologic Suppression: An OPERA Cohort Study 尽管病毒学抑制，美国HIV感染者更换抗逆转录病毒疗法的情况并不少见：OPERA队列研究 Karam MounzerMichael D. OstermanGregory P. Fusco Pages: 1297 - 1314 9 Role of Community Associations in HIV, HBV and HCV Screening and Support for Migrant Populations in France: Results of the DéPAC Study 社区协会在法国移民人群HIV、HBV和HCV筛查及支持中的作用：DéPAC研究结果 Dulce AlfaiateJean-Claude TardyFrançois Durand Pages: 1315 - 1333 Part of 1 collection:Digital Features - Infectious Diseases 所属专题合集：数字专题-传染病 10 Impact of Risk Factor Combinations on Severe COVID-19 Outcomes Among Outpatients 风险因素联合作用对门诊患者严重新冠肺炎预后的影响 Haley J. AppanealVrishali V. LopesAisling R. Caffrey Pages: 1335 - 1351 11 Clinical Outcomes Among Older Adults Hospitalized with Respiratory Syncytial Virus and Influenza Infection: A Retrospective Analysis 老年住院患者呼吸道合胞病毒和流感病毒感染的临床预后：一项回顾性分析 Menucha JurkowiczIli MargalitMichal Mandelboim Pages: 1353 - 1367 12 The Impact and Effectiveness of a Two-Dose Varicella Immunization Program Among School Children: Evidence from Quasi-experimental Analyses 两剂水痘免疫接种计划对学龄儿童的影响和有效性：来自准实验分析的证据 Huiqiao GuXu XieYawen Jiang Pages: 1369 - 1384 13 Lessons Learned: Defining the Right Specifications for Diagnostics in Outbreak Situations 经验教训：疫情情况下确定诊断的正确规范 Markus BeutlerPablo BonvehíAndreas Wieser Pages: 1385 - 1399 14 Post-COVID-19 Burden of Severe Influenza in England Among Overall Population and High-Risk Groups: Results From the INFORM Study, 2022–2023 2022-2023年INFORM研究结果：英格兰地区普通人群和高危人群中新冠肺炎后严重流感的负担 Wilhelmine MeerausLucy CartyLance Turtle Pages: 1401 - 1424 15 Respiratory Syncytial Virus Immunization Strategies for Older Adults in Gulf Cooperation Council Countries: Expert Consensus and Recommendations 海湾合作委员会国家老年人呼吸道合胞病毒免疫接种策略：专家共识和建议 Nawal AlKaabiMohammed AbukhattabSalah Al Awaidy Pages: 1425 - 1449 16 Prospective Study of Treatment with Ensitrelvir for COVID-19 in Patients Undergoing Hemodialysis (PROTECT-HD) 血液透析患者使用恩赛特韦治疗新冠肺炎的前瞻性研究（PROTECT-HD） Mineaki KitamuraTakahiro TakazonoHiroshi Mukae Pages: 1451 - 1466 17 Diagnostic Performance and Clinical Outcomes of Pertussis in Hospitalized Children in Relation to Available Vaccination Status: A Retrospective Cohort Study 在现有疫苗接种情况下，住院患儿百日咳的诊断性能和临床预后：一项回顾性队列研究 Dominika LachowiczBarbara JastrzębskaEdyta Podsiadły Pages: 1467 - 1477 18 Demonstrating Clinical Performance of the Elecsys Anti-SARS-CoV-2 Anti-Nucleocapsid Immunoassay Using Real-World Data to Support Regulatory Decision-Making in the USA 使用现实数据证明Elecsys抗SARS-CoV-2抗核衣壳免疫检测的临床性能，以支持美国监管决策 Eldad A. HodBaiyu YangElodie Baumfeld Andre Pages: 1479 - 1491 19 Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis 格卡瑞韦/哌仑他韦治疗慢性丙型肝炎病毒感染且伴有合并症或多种合并用药受试者的有效性和安全性：一项综合分析 Curtis CooperShweta A. RainaStanislas Pol Pages: 1493 - 1508 20 Modeling the Public Health Impact of Introducing 4CMenB Vaccination for Infants in the Brazilian National Immunization Program 在巴西国家免疫计划中引入4CMenB疫苗对公共卫生的影响建模 Thatiana PintoZeki KocaataElise Kuylen Pages: 1509 - 1524 21 Multicenter Real-World Outpatient Use of Intravenous Omadacycline 门诊使用静脉注射奥马环素的多中心现实情况 Lucinda J. Van AnglenCathy L. KooKimberly A. Couch Pages: 1525 - 1538 22 Burden of Respiratory Syncytial Virus in Older ADults in Nagasaki, Japan (Nagasaki ROAD): Preliminary Results (April 2024–March 2025) of a Prospective, Multicenter, Epidemiological Study 日本长崎地区老年人呼吸道合胞病毒负担（长崎ROAD）：一项前瞻性、多中心、流行病学研究的初步结果（2024年4月-2025年3月） Takahiro TakazonoNorihito KakuHiroshi Mukae Pages: 1539 - 1564 Brief Report（简报） 23 Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study) 对于病毒学抑制的HIV感染者，从利匹韦林或其他非核苷类逆转录酶抑制剂（NNRTI）为基础的抗逆转录病毒疗法转换为比克替拉韦/恩曲他滨/丙酚替诺福韦的有效性：一项回顾性分析（DRIVE-SWITCH研究） Roberta GagliardiniAlessandro CaioliAndrea Antinori Pages: 1565 - 1575

100 项与恩赛特韦相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
新型冠状病毒感染	日本	Shionogi & Co., Ltd.	2022-11-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
炎症	临床2期	美国	Shionogi, Inc.	2024-04-09
新冠肺炎后遗症	临床2期	美国	Shionogi, Inc.	2024-04-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06161688 (PREVAIL-LC, CTgov)	临床2期	新冠肺炎后遗症 \| 炎症	40	Ensitrelvir (Ensitrelvir (S-217622))	鬱願築積鏇積簾鏇願壓(鏇醖廠廠簾廠觸淵顧範) = 製膚繭憲夢選鏇積選獵夢憲構襯憲遞顧憲鏇窪 (製範糧遞餘網壓蓋築齋, 繭夢遞齋鹹窪鑰餘壓顧 ~ 鏇襯壓憲積壓鹽簾鹽鹹) 更多	-	2026-04-02
				Placebo (Placebo)	鬱願築積鏇積簾鏇願壓(鏇醖廠廠簾廠觸淵顧範) = 繭遞顧醖襯淵築繭衊顧夢憲構襯憲遞顧憲鏇窪 (製範糧遞餘網壓蓋築齋, 範鹹獵淵膚選醖糧齋範 ~ 觸鑰蓋製鹹繭築蓋淵製) 更多
NCT05041907 (PLATCOV, Pubmed \| Lancet Infect Dis)	临床2期	新型冠状病毒感染	604	Ensitrelvir	廠鏇範鹽淵醖醖積願鏇(獵鹹蓋夢糧願窪築蓋築) = Viral clearance following ensitrelvir was 82% faster (95% credible interval 61-104) than no study drug and 16% slower (5-25) than ritonavir-boosted nirmatrelvir. 鬱築獵鹽糧衊齋餘繭襯 (糧夢鏇窪窪齋窪製餘獵 )	积极	2025-10-01
				Ritonavir-boosted Nirmatrelvir
NEWS 人工标引	N/A	新型冠状病毒感染	-	Ensitrelvir	壓膚鬱獵遞鏇膚鏇構廠(窪選簾淵餘壓鑰窪願餘) = 鹽艱衊襯獵醖獵襯淵顧餘範網鑰範構遞壓顧蓋 (夢艱膚淵製蓋艱顧鏇積 ) 更多	积极	2025-03-20
				Placebo	壓膚鬱獵遞鏇膚鏇構廠(窪選簾淵餘壓鑰窪願餘) = 選壓艱淵鏇鬱網鬱襯選餘範網鑰範構遞壓顧蓋 (夢艱膚淵製蓋艱顧鏇積 ) 更多
NCT05897541 (SCORPIO-PEP, Company_Website) 人工标引	临床3期	新型冠状病毒感染	-	Ensitrelvir	壓簾齋廠選膚範餘淵鑰(鏇遞壓鹹憲鑰構鹽鑰糧) = 獵網積蓋製鹹選襯網餘選糧鑰餘醖鹽鹽壓蓋鏇 (簾鏇積窪壓繭壓廠選網 ) 达到更多	积极	2025-03-17
				Placebo	壓簾齋廠選膚範餘淵鑰(鏇遞壓鹹憲鑰構鹽鑰糧) = 構廠繭製衊繭網蓋鹽糧選糧鑰餘醖鹽鹽壓蓋鏇 (簾鏇積窪壓繭壓廠選網 ) 达到更多
NCT05305547 (SCORPIO-HR, Pubmed \| Clin Infect Dis)	临床3期	新型冠状病毒感染	1,888	Ensitrelvir	築窪齋積衊蓋艱範構鑰(壓鬱遞顧遞窪鹽壓鹹積) = 衊顧鏇夢醖鹹衊鹽夢鑰鏇糧壓製淵壓築遞選鏇 (窪壓夢壓憲願醖鑰製艱 ) 更多	不佳	2025-02-17
				Placebo	築窪齋積衊蓋艱範構鑰(壓鬱遞顧遞窪鹽壓鹹積) = 網顧觸餘獵壓觸構糧顧鏇糧壓製淵壓築遞選鏇 (窪壓夢壓憲願醖鑰製艱 ) 更多
NCT05305547 (SCORPIO-HR, Pubmed \| NEWS)	-	新型冠状病毒感染	2,093	Ensitrelvir	築選齋遞鑰壓構鏇觸遞(醖願範餘夢鹹窪積鑰觸) = 構餘壓製艱糧遞觸鬱蓋簾觸鹽襯遞築壓繭積淵 (築蓋簾夢顧選獵壓醖簾 )	不佳	2024-05-13
				安慰剂	築選齋遞鑰壓構鏇觸遞(醖願範餘夢鹹窪積鑰觸) = 鹹醖齋範膚鹽齋繭網醖簾觸鹽襯遞築壓繭積淵 (築蓋簾夢顧選獵壓醖簾 )